Atorvastatin in Factorial with Omega-3 Fatty Acids Risk Reduction in Diabetes

Home page

The Atorvastatin in Factorial with Omega-3 fatty acids Risk Reduction in Diabetes (AFORRD) study was a one-year, community-based, multi-centre, randomised controlled trial assessing the degree to which a statin and/or omega-3 fatty acids reduce the estimated risk of coronary heart disease (CHD) in 1,000 people with Type 2 diabetes.

Principal Investigators: Professor Rury Holman and Professor Andrew Neil
Co-Investigator: Dr Andrew Farmer
Senior Project Manager: Lynne Tucker
Study Manager: Dr Lucielle Mansfield
ISRCTN number: 76737502

News

Show all

2006	August	Last Patient Last Visit
2005	July	AFORRD finished patient recruitment on 31st July 2005 and successfully randomised 800 participants.